Use of human epidermal growth factor receptor 2 (HER2)-targeting agents is currently the therapy of choice in the adjuvant setting for HER2+ breast cancer; the desire to improve survival rates has led to its use in the neoadjuvant setting. Still, clinicians have contrasting perceptions of the value of neoadjuvant therapy in this setting, and may not effectively interpret the clinical significance of emerging data regarding such therapy, resulting in suboptimal care. To explore core clinical management challenges in this disease setting, this activity features a panel of 4 clinical experts from the disciplines of surgical oncology, clinical pathology, radiation oncology, and medical oncology using a tumor board format to discuss the case a 61-year-old woman who is postmenopausal and has T2 N3 breast cancer that is HER2+ and is estrogen receptor negative (ER-) and progesterone receptor negative (PR-).
Earn accreditation for this activity at the following location:
© 2015 Imedex, LLC.